We read with interest the recently published paper by Truini and colleagues (1) describing the peculiar in vitro activity of afatinib on non–small cell lung cancer cell lines harboring the EGFR L747-A750>P mutation. We reviewed our patient database and found 6 cases out of 265 with this specific EGFR mutation (2.2%), similar to the prevalence reported in the paper by Truini and colleagues. Here we report two of those cases, one treated in first-line with afatinib and the other with erlotinib followed by osimertinib at progression.
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter / Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Conci N.; Minari R.; Tiseo M.; Ardizzoni A.. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - ELETTRONICO. - 26:2(2020), pp. 518-519. [10.1158/1078-0432.CCR-19-2441]
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter
Di Federico A.
;Filippini D. M.
;Dall'Olio F. G.
;Conci N.
;Ardizzoni A.
2020
Abstract
We read with interest the recently published paper by Truini and colleagues (1) describing the peculiar in vitro activity of afatinib on non–small cell lung cancer cell lines harboring the EGFR L747-A750>P mutation. We reviewed our patient database and found 6 cases out of 265 with this specific EGFR mutation (2.2%), similar to the prevalence reported in the paper by Truini and colleagues. Here we report two of those cases, one treated in first-line with afatinib and the other with erlotinib followed by osimertinib at progression.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
